It is being developed by Eli Lilly and Company, and whilst Phase 3 trials are anticipated, no approval timeline has been confirmed
BPC-157 charakterystyka odczynnika chemicznego BPC-157 (Body Protection Compound 157) jest syntetycznym peptydem badawczym opisywanym w literaturze naukowej jako materia referencyjny wykorzystywany w badaniach biochemicznych i biologii molekularnej
Woods CM, Fernandez C, Kunze KL, Atkins WM: Allosteric activation of cytochrome P450 3A4 by alpha-naphthoflavone: branch point regulation revealed by isotope dilution analysis
small sample size, lack of control group, lack of common diagnosis), it did demonstrate improved pain in 87.5% of patients who received injections containing BPC-157
It can take many years (approx 20) to develop a deficiency disease in those altering their diet to one lacking in B12 due to reabsorbtion however, if failure to absorb leads to B12 deficiency disease occur within a few years (3-4)